Physician profile
Angela D Meyer
NPI 1649249087
$2,375.26
in general payments reported to CMS, 2019-2025
35 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $91.10 · 2021: $242 · 2022: $373 · 2023: $231 · 2024: $548 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $366.78 | 2023-2025 | |
| Abbvie INC. | $365.98 | 2019-2023 | |
| Exeltis, USA INC. | $222.88 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $132.89 | 2024-2025 | Veozah |
| Scynexis, INC. | $88.86 | 2022 | |
| Hologic Sales and Service, LLC | $87.44 | 2019-2025 | Fetal Fibronectin Enzyme Immunoassay, Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $83.42 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $80.40 | 2024 | Myfembree, Gemtesa |
| Organon LLC | $78.16 | 2022-2025 | Nexplanon |
| Coopersurgical, INC. | $69.87 | 2019-2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $67.25 | 2019-2025 | Gardasil 9 |
| Evofem Biosciences, INC. | $67.15 | 2021-2023 | Phexxi |
| Lupin INC. | $50.72 | 2019-2020 | |
| Daiichi Sankyo INC. | $50.43 | 2019-2025 | Injectafer |
| Agile Therapeutics, INC. | $50.32 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $49.66 | 2019-2020 | |
| Avion Pharmaceuticals | $48.79 | 2019-2022 | |
| Millicent US INC | $47.94 | 2019-2025 | Intrarosa, Femlyv |
| Biogen, INC. | $38.93 | 2025 | Zurzuvae |
| Teleflex LLC | $30.51 | 2019 | |
| Mylan Pharmaceuticals INC. | $28.73 | 2019 | |
| Amgen INC. | $27.94 | 2019 | |
| Minerva Surgical, INC | $24.73 | 2019-2025 | |
| Coloplast Corp | $23.83 | 2023 | Altis |
| Amag Pharmaceuticals, INC. | $23.63 | 2019 | |
| Exact Sciences Corporation | $22.43 | 2024 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $21.95 | 2023 | Bd Max System, Bd Max Instrument |
| Bayer Healthcare Pharmaceuticals INC. | $19.86 | 2025 | |
| Novo Nordisk INC | $18.13 | 2023 | Wegovy |
| Davol INC. | $17.55 | 2022 | |
| Currax Pharmaceuticals LLC | $16.47 | 2024 | Contrave |
| Avanos Medical | $15.53 | 2023 | On-Q* Pump and Accessories |
| Therapeuticsmd, INC. | $12.38 | 2019 | |
| Allergan, INC. | $12.25 | 2019 | |
| Channel Medsystems, INC. | $11.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.